May 13, 2024

CareCloud Rejects Unsolicited Takeover; Shares Surge 90%

Shares in healthcare technology solutions company, CareCloud, Inc (Nasdaq: CCLD), surged more than 90% in morning trading on Monday after the company announced its Board had rejected an unsolicited takeover bid. CareCloud led the PRISM Emerging Healthcare Index during the day. CareCloud said in a statement that the unsolicited, non-binding indication of interest proposed to… [Read More]
May 12, 2024

EV companies Rivian, Lucid and others compile cash and reassure Wall Street

Previously thriving electric vehicle startups, buoyed by low interest rates, abundant capital, and Wall Street’s favorable outlook, are now hustling to demonstrate their resilience amid challenging market conditions, with some even declaring bankruptcy. Prominent on their agenda is cash conservation. Leaders from Rivian Automotive ,Lucid Group and Nikola Corp have outlined their strategies to decrease expenses… [Read More]
May 11, 2024

A Changing Landscape: AI In Biotechnology

The use of artificial intelligence (AI) in biotechnology offers companies a compelling opportunity to accelerate and optimize drug development, a process that is time consuming, costly and has a high risk of failure. Beyond improving drug discovery, there is enormous potential for AI in enabling personalized medicine, enhancing diagnostic accuracy, delivering analytics, and assisting with… [Read More]
May 10, 2024

Incannex Completes IND Meeting for Development of CBD CannQuit-O for Opioid Use Disorder

Australian psychedelic medicine company, Incannex Healthcare Inc. (Nasdaq: IXHL), has successfully completed a pre-IND (Investigational New Drug) meeting with the FDA regarding the development of CannQuit-O for treatment of Opioid Use Disorder (OUD). CannQuit-O is a chewable tablet that offers rapid and sustained release of its active ingredients, including an opioid agonist, antagonist and cannabidiol… [Read More]
Test tubes filled with liquid using a dropper
May 10, 2024

Annovis Bio Untangles Potential Error in Phase 3 Study, Shares Surge 25%

After discovering an error that might have rendered its Phase 3 study of buntanetap in early Parkinson’s disease (PD) “worthless”, Annovis Bio, Inc. (NYSE: ANVS) spent two months untangling the issue that led to too many plasma samples being completely free of buntanetap. The company’s share price was up 25.10% at the close of Thursday’s… [Read More]
Overweight person measuring waist with a tape measure
May 10, 2024

NeuroBo Shares Rise on First Quarter Accomplishments and Clinical Updates

NeuroBo Pharmaceuticals (Nasdaq: NRBO) has announced its financial results for the first quarter ended March 31, 2024. During the period, the company achieved a number of important milestones, including receiving FDA clearance for its Investigational New Drug (IND) application for a Phase 1 clinical trial of DA-1726 in obesity, completing enrollment of Part 1 of… [Read More]